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Abstract
Although lymphomas are generally considered as tumors of 
lymph nodes about 25-40% arise at extranodal sites. We report 
a case of a 60 years old female who developed a right breast 
B-diffuse large cell non-Hodgkin lymphoma in 2005 treated by 
chemo/radio-therapy which relapsed at the same breast in 2007 
and at the other breast in 2010. The patient underwent both 
radiologic and nuclear medicine studies.
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Introduction
Hematopoietic malignancies can be encountered in the 
breast and can occasionally mimic primary breast cancers. 
Although lymphomas are generally considered as tumors of 
lymph nodes about 25–40% arise at extranodal sites [1, 2] and 
it’s important to distinguish them from secondary extranodal 
involvement by disseminated nodal disease. Despite there isn’t 
a precise and agreed definition, extranodal lymphomas are con-
sidered all lymphomas confined to a solitary extranodal site (and 
possibly its contiguous lymph nodes) or, at least and less strictly, 
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a lymphoma which presents the main bulk of diseases at an ex-
tranodal site [2, 3]. Wiseman and Liao [4] have proposed that the 
diagnosis of primary breast non-Hodgkin lymphoma (PBNHL) 
must satisfy three criteria: 1) adequate pathologic evaluation, 
2) both mammary tissue and lymphomatous infiltrate in close 
association, and 3) exclusion of either systemic lymphoma or 
previous extramammary lymphoma. PBNHL are mainly diffuse 
large B-cell non-Hodgkin lymphoma (B-DLC-NHL) and are very 
rare, accounting for 2.2% of all extranodal lymphomas [1] and for 
0.04% to 0.5% of malignant breast neoplasms [4–7]. The most 
common symptom of primary breast lymphoma is a palpable lump 
but it may also present as breast enlargement [8]. The natural 
history of primary breast NHL is different from that of extra nodal 
NHL at other sites, because of its rapid progression and worse 
prognosis [9]; Giardini et al. have reported a total five-year survival 
rate of 43% [10]. 
Case report
We report a case of a 60 year old female who developed a right 
breast B-diffuse large cell non-Hodgkin lymphoma (B-DLC-NHL) 
in 2005. A 67Gallium-citrate (67Ga-citrate) scintigraphy 
was performed before and after chemo/radio-therapy document-
ing complete response and disappearance of the pathologic up-
takes (Figure 1). 67Ga-citrate scintigraphy was performed injecting 
intravenously an activity of 185MBq, acquiring total body planar 
images (anterior and posterior view) and tomographic studies of 
the thorax 3 days after injection on a dual headed Adac-Vertex 
Philips gamma camera (Philips Healthcare, Andover, MA, USA; 
medium energy collimator; speed 11cm/min; butterworth filter). In 
2007 a 18fluorodeoxyglucose-positron emission tomography/com-
puted tomography (F18-FDG-PET/CT) revealed right breast 
relapse of the NHL (Figure 1). F18-FDG-PET/CT was performed 
in the fasting state for at least 6 hours and the glucose level lower 
than 150mg/dl. An FDG dose of 5.5 mega-Becquerel (MBq)/Kg 
was administered intravenously and a 2D mode ordered-sub-
set-expectation-maximization (OS-EM) imaging was acquired 
60 minutes after injection on a Discovery ST PET/CT tomograph 
(General Electric Company - GE® - Milwaukee, WI, USA) with 
standard CT parameters (80 mA, 120 Kv without contrast; 4 min-
utes per bed-PET-step of 15cm). The reconstruction was performed 
in a 128 × 128 matrix and 60 cm field of view. PET images were 
analyzed visually and semi-quantitatively by measuring the maxi-
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mum standardized uptake value (SUVmax). SUV was expressed 
as SUVbody weight (SUVbw – g/ml) and automatically calculated 
by the software (Volumetrix for PET/CT; Xeleris™ Functional imag-
ing workstation; GE®). The patient underwent chemotherapy and 
right mastectomy. In 2008 and 2009 F18-FDG-PET/CT studies were 
negative (Figure 1). In 2010 was demonstrated a disease relapse 
at left breast; in particular, mammography revealed parenchymal 
areas without the fibro-adipose changes characterizing the rem-
nant surrounding tissue (Figure 2). Mammography was acquired 
on Senographe Essential digital acquisition system (General 
Electric Company-GE®-Milwaukee, WI, USA; 31kV, 149mAs, Rh/Rh, 
Grid, AOP/STD 9, clan 79mm; WW:900, WL:2683, Zoom:0.69 ROT, 
Inc: Ø°-45°, AGD:2.07mGy, ESE:17.05mGy). Breast ultrasonog-
raphy was acquired on a LOGIQ S6 (General Electric Company-
GE®-Milwaukee, WI, USA; 11 Mhz probe) and revealed 3 large 
hypo-isoechoic nodules and no involvement of omolateral axillary 
lymph nodes (Figure 2). F18-FDG-PET/CT documented 6 patho-
logic uptakes at left breast (Figure 2). A breast biopsy confirmed 
the relapse of B-DLC-NHL and the patient started chemotherapy 
at the end of which, in 2011, a new F18-FDG-PET/CT showed 
complete disappearance of the pathologic uptakes (Figure 2). 
A written consensus was obtained by the patient before each study. 
Discussion 
Primary lymphomas of the breast are uncommon [1, 11] 
and, although rare, bilateral breast involvement has also been 
reported [12]. The old history of breast B-DLC-NHL relapsed 
twice after therapy, firstly at the same breast and subsequently 
at the other, makes this case of unique interest also because of 
the concurrent use of radiologic and nuclear medicine imag-
ing. Despite the radiologic features are non-specific and the 
diagnosis cannot be made on the basis of imaging only, it’s very 
relevant in establishing disease extent, possible involvement of 
other sites and therapy planning. Therapeutic procedures mainly 
rely on chemotherapy and radiotherapy [8, 13, 14] while surgery 
has had a progressive decline [15–17]. PBNHL doesn’t show 
specific mammographic features; most commonly it has been 
reported as well-circumscribed lesion without calcifications or 
desmoplastic reaction, but also as lesion with sharp or minimally 
irregular margins, and less commonly as diffuse increased paren-
chymal density with skin thickening or as miliary densities [8, 13, 
18–20]. Bilateral miliary densities on mammography have been 
reported in secondary involvement of the breast by NHL [20]. At 
ultrasonography examination breast lymphomas are generally 
described as masses that could be well or poorly defined, with 
an hypo- or hyperechoic aspect and showing both a focal and 
diffuse parenchymal involvement [21, 22]. In a recent study Li et 
al. have retrospectively reviewed 11 patients with PBNHL showing 
that the echo pattern of the mass was hypoechoic in 10 lesions, 
hyperechoic in 1 and complex echoic in 2; moreover no mass had 
speculated margins or calcifications and ipsilateral axillary lymph 
node involvements were noted in 6 patients [23]. Despite literature 
is poor and few data concerning radiological features of PBNHL are 
available in particular for magnetic resonance (MR), it seems to be 
relevant mainly in establishing the extent of disease, in the assess-
ment of therapy response and in the diagnosis of recurrence. Rizzo 
et al. [13] evaluated 7 patients with PBNHL by MR suggesting that 
the occurrence of PBNHL should be considered in the presence 
of large enhancing lesions of the breast, especially if associated 
with skin thickening. They have found a mass-like enhancement 
with round shape, smooth margins, homogeneous enhancement 
Figure 1. 67Ga-citrate anterior (1-A1) and posterior view (1-A2) of the total body planar images performed in 2005, revealing high pathologic 
uptake at right breast; anterior (1-B1) and posterior (1-B2) 67Ga-citrate images after chemotherapy revealing no pathologic uptake; anterior 
maximum intensity projection view of F18-FDG-PET/CT (1-C1) at first omolateral relapse in 2007; anterior maximum intensity projection view of 
F18-FDG-PET/CT performed in 2008 (1-C2) after chemotherapy and in 2009 during follow-up (1-C3) confirming the absence of pathologic uptakes
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pattern, peak enhancement value of 90% and kinetics with slow 
rise and delayed plateau. Demirkazik et al. and Mussurakis et al. 
described multiple well- or ill-defined nonspiculated hypointense 
masses on T1 weighted images [19, 22]. Darnell et al. described 
a single, large, well-circumscribed mass, isointense relative to 
parenchyma on T1 images, associated with enhancing skin thick-
ening [9]. A possible important role of MR seems to be its ability 
to evaluate multicentricity and multifocality of lesions as demon-
strated by Kiresi et al. [24]; moreover, Espinosa et al. showed that 
MR could be more accurate than mammography and ultrasonog-
raphy in detecting and staging multifocal breast lymphoma and 
it’s very useful in the therapy response evaluation [25]. Although 
in the past 67Ga-citrate scintigraphy was an important tool for the 
evaluation of lymphomas, nowadays its role is very limited and 
it’s not recommendable for dosimetric concerns and diagnostic 
accuracy; despite this, in a recent study by Takemura et al, pub-
lished in 2009, a PBNHL was studied with this tracer [26].
F18-FDG-PET/CT role in the management of high-grade 
NHL and Hodgkin Disease is well established and many data 
are available in literature about its usefulness in evaluating ex-
tranodal lymphomas (bone, nasal region, pituitary, testis, ocular 
region, thyroid, adrenal) [27–33]. There are few reports on the 
role of F18-FDG-PET/CT for the management of PBNHL [34–38]. 
Most studies are case reports with few exceptions [38, 39] and 
in all cases is reported high FDG uptake. Yang et al. [38] studied 
with F18-FDG-PET/CT 13 tumors in 10 patients (three had bilat-
eral tumors) and 12 (92%) tumors showed diffuse and intense 
hypermetabolic activity. All 10 patients underwent follow-up to 
evaluate response to chemotherapy and all 12 initially positive 
tumors showed complete resolution of hypermetabolism. In a re-
cent study by Santra et al. [39] were evaluated 18 patients affected 
by breast lymphoma (16 unilateral and 2 bilateral); the indication 
was staging in 12 patients, evaluation of treatment response in 12 
and restaging in 3. F18-FDG-PET/CT demonstrated high uptake 
in the masses despite non distinguishable from uptake of primary 
breast cancer or any other glucose avid tumor; F18-FDG-PET/CT 
was useful for staging, therapy response evaluation and restaging 
like in high-grade nodal and extranodal NHL. 
To summarize, mammography and ultrasonography despite 
not specific have a primary role in the diagnosis while MR seems to 
be relevant in establishing the extent of disease, therapy response 
assessment, diagnosis of recurrence and multifocal lesion. Our 
case confirms the possible usefulness of F18-FDG-PET/CT in 
the management of PBNHL both in terms of staging, treatment 
response assessment and restaging, like in high-grade nodal and 
extranodal NHL. 
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